OncoMatch

OncoMatch/Clinical Trials/NCT07106671

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Is NCT07106671 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Siltuximab for crs - cytokine release syndrome.

Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07106671Data as of Jun 2026Location: China

Treatment: SiltuximabThis is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Siltuximab

Cancer type

Multiple Myeloma

Prior therapy

Must have received: CAR-T cell therapy

after CAR-T treatment

Lab requirements

Blood counts

Platelet count <75,000/μL, absolute neutrophil count <1,000/μL, or hemoglobin <60 g/L at screening [excluded]

Kidney function

Creatinine clearance <30 mL/min [excluded]

Liver function

ALT or AST >3× ULN, or bilirubin >2× ULN [excluded]

Cardiac function

Known severe cardiac conditions, including NYHA class III/IV heart failure, uncontrolled angina, arrhythmia, or hypertension, myocardial infarction within 6 months, or other uncontrolled/severe cardiovascular diseases, including prior cerebrovascular events with residual deficits [excluded]

Creatinine clearance <30 mL/min. Platelet count <75,000/μL, absolute neutrophil count <1,000/μL, or hemoglobin <60 g/L at screening. ALT or AST >3× ULN, or bilirubin >2× ULN. Known severe cardiac conditions, including NYHA class III/IV heart failure, uncontrolled angina, arrhythmia, or hypertension, myocardial infarction within 6 months, or other uncontrolled/severe cardiovascular diseases, including prior cerebrovascular events with residual deficits.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07106671 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received CAR-T cell therapy.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify